The Multi-Society Task Force, in collaboration with invited experts, developed guidelines to assist health care providers with the appropriate provision of genetic testing and management of patients at risk for and affected with Lynch syndrome as follows: Figure 1 provides a colorectal cancer risk assessment tool to screen individuals in the office or endoscopy setting; Figure 2 illustrates a strategy for universal screening for Lynch syndrome by tumor testing of patients diagnosed with colorectal cancer; Figures 3 -6 provide algorithms for genetic evaluation of affected and at-risk family members of pedigrees with Lynch syndrome; Table 10 provides guidelines for screening at-risk and affected persons with Lynch syndrome; and Table 12 lists the guidelines for the management of patients with Lynch syndrome. A detailed explanation of Lynch syndrome and the methodology utilized to derive these guidelines, as well as an explanation of, and supporting literature for, these guidelines are provided.
Introduction
Colorectal cancer (CRC) is a major American health problem that ranks as the second leading cause of cancer death after lung cancer. In the United States, approximately 143,000 new cases are diagnosed each year, and 51,000 Americans die annually from this disorder (1).
The cause of CRC is multifactorial, with environment and inheritance playing varying roles in different patients (2) . Approximately 70-80% of patients with CRC seem to have sporadic disease with no evidence of an inherited disorder. In the remaining 20-30%, a potentially definable inherited component might be causative (3).
Lynch syndrome (LS), an autosomal dominant condition, is the most common cause of inherited CRC, accounting for about 3% of newly diagnosed cases of colorectal malignancy (4-8). The eponym "Lynch syndrome" recognizes Dr Henry T. Lynch, the first author on the original 1966 publication that comprehensively described this condition (9).
In the early 1990s, mutation of genes in the DNA mismatch repair (MMR) pathway were implicated as the cause of LS (10-13), and the presence of the mutations now defines the syndrome. Since then, germline testing with increasing sensitivity has been available for patients, as additional genetic discoveries have occurred. When used appropriately, genetic testing for LS can confirm the diagnosis at the molecular level, justify surveillance of at-risk persons, decrease the cost of surveillance by risk stratification, aid in surgical and chemoprevention management, and help in decisions concerning family and career planning. However, when used inappropriately, genetic testing can misinform affected patients with false-negative results and waste patient and societal resources.
The goal of this consensus document is to critically analyze the current literature and provide "best practice" evidence-based recommendations for diagnosis and management strategies to health care providers caring for these patients.
Terminology/differential diagnosis HNPCC designates patients and / or families who fulfill the Amsterdam I or II criteria. LS is applied to patients and families in which the genetic basis can be linked to a germline mutation in one of the DNA MMR genes or the EPCAM gene. Lynch-like syndrome describes patients and / or families in which molecular testing demonstrates the presence of MSI and / or abnormalities in the expression of MMR gene proteins on IHC testing of tumor tissue expression, but no pathogenic germline mutation can be found in the patient (e.g., in the absence of a BRAF mutation and / or MLH1 promoter hypermethylation when there is loss of tumor expression of the MLH1 protein). In a recent publication, about half of LLS patients had biallelic somatic mutations of MLH1 or MSH2 to explain the MMR deficient tumors without having causal germline or promotor mutations (68). a LS-associated tumors include tumor of the colorectum, endometrium, stomach, ovary, pancreas, ureter, renal pelvis, biliary tract, brain, small bowel, sebaceous glands, and kerotoacanthomas. 
GENETIC ALTERATIONS

IDENTIFICATION OF LYNCH SYNDROME GENETIC TESTING
Guideline
Testing for MMR deficiency of newly diagnosed CRC should be performed. This can be done for all CRCs, or CRC diagnosed at age 70 years or younger, and in individuals older than 70 years who have a family history concerning for LS. Analysis can be done by immunohistochemistry (IHC) testing for the MLH1/MSH2/MSH6/PMS2 proteins and/or testing for MSI. Tumors that demonstrate loss of MLH1 should undergo BRAF testing or analysis of MLH1 promoter hypermethylation (Figure 2) . To facilitate surgical planning, tumor testing on suspected CRC should be performed on pre-operative biopsy specimens, if possible. This guideline is a strong recommendation, with evidence level III, and GRADE moderate-quality evidence.
Individuals who have a personal history of a tumor showing evidence of MMR deficiency (without evidence of MLH1 promoter methylation); uterine cancer diagnosed at younger than age 50 years; a known family MMR gene mutation; fulfill Amsterdam criteria or revised Bethesda guidelines; and / or have a personal risk of ≥ 5 % chance of LS based on prediction models should undergo genetic evaluation for LS (Figures 3 -6) . This guideline is a strong recommendation, with evidence level III, and GRADE moderate-quality evidence.
LYNCH SYNDROME MANAGEMENT Guideline
Screening for CRC by colonoscopy is recommended in persons at risk (first-degree relatives of those affected) or affected with LS every 1 to 2 years, beginning between ages 20 -25 years or 2 -5 years before the youngest age of diagnosis of CRC in the family if diagnosed before age 25 years. In surveillance of MMR germline mutation-positive patients, consideration should be given to annual colonoscopy. The age of onset and frequency of colonoscopy in this guideline is in agreement with most organizations and authorities (122,131,136 -138) . This guideline is a strong recommendation, with evidence level III, and GRADE moderate-quality evidence (Table 10 ). In carriers of deleterious MSH6 and PMS2 mutations, the risk of CRC is lower and age at diagnosis later (22,25) than in patients with MLH1 and MSH2 mutations. In these affected individuals, consideration could be given to starting screening at age 30 years in MSH6 and 35 years in PMS2 carriers, unless an early-onset cancer exists in a given family.
Guideline
Screening for EC should be offered to women at risk for or affected with LS by pelvic examination and endometrial sampling annually starting at age 30-35 years ( Table 10 ). The strength of evidence for this guideline is expert consensus-level V, GRADE low-quality evidence, and is in concert with other expert opinion (122, 137, 138) .
Screening for ovarian cancer should be offered to women at risk for or affected with LS by transvaginal ultrasound annually starting at age 30-35 years ( Table 10 ). The strength of evidence for this guideline is expert consensus-level V and GRADE low-quality evidence. In the absence of data on this issue, several consensus panels have suggested that transvaginal ultrasound for ovarian cancer is a screening consideration in LS (122, 137, 138) . 
